Preliminary estimates released by the U.S. Centers for Disease Control and Prevention show that drug overdose deaths in the United States fell by nearly 14% in 2025 compared with the year before, marking the third consecutive annual decline.
The provisional figures indicate that nearly 69,973 people died from drug overdoses in 2025, down from an estimated 81,313 deaths in 2024. Public health experts point to the broad availability of naloxone - a potent antidote used to reverse opioid overdoses - as a significant factor in the reduction in fatalities.
Opioid-related deaths also declined. The CDC estimates fatalities involving opioids fell to 44,564 in 2025 from 55,296 the previous year. Despite this overall drop, synthetic opioids, including fentanyl, continue to be the single largest contributor to overdose deaths nationwide.
While most states reported decreases in overdose fatalities, the CDCs provisional report notes notable exceptions. New Mexico, Arizona and Colorado each experienced increases in overdose deaths of 10% or more compared with the same period in 2024.
What the data show
- Overall estimated drug overdose deaths fell to nearly 69,973 in 2025 from 81,313 in 2024.
- Estimated opioid-involved deaths declined to 44,564 in 2025 from 55,296 in 2024.
- Synthetic opioids, including fentanyl, remain the largest single contributor to overdose fatalities.
- Most states reported declines, but New Mexico, Arizona and Colorado each saw increases of 10% or more year-over-year.
Context and caveats
The numbers cited are provisional estimates provided by the CDC. As with provisional data, final counts may be revised as additional information becomes available. Experts cited in the CDC coverage emphasize the role of naloxone access in reducing deaths, while the persistence of synthetic opioids is cited as an ongoing driver of mortality.
Implications
The decline in estimated overdose deaths suggests progress in overdose response and intervention efforts, particularly the distribution and use of naloxone. Nevertheless, the continued prominence of synthetic opioids and the rise in fatalities in certain states highlight ongoing public health challenges.